drugset / Trial / NCT00030901
S9917, Selenium in Preventing Cancer in Patients With Neoplasia of the Prostate
Phase 3
Completed
619 enrolled
SWOG Cancer Research Network
Cancer and Leukemia Group B · collabEastern Cooperative Oncology Group · collabNational Cancer Institute (NCI) · collab
RandomizedParallel-groupTriple-blindPrevention
Summary
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. The use of selenium may be an effective way to prevent prostate cancer in patients who have neoplasia of the prostate. PURPOSE: Randomized phase III trial to study the effectiveness of selenium in preventing prostate cancer in patients who have neoplasia of the prostate.
Timeline
- Start
- 2000-02
- Primary completion
- 2011-11
- Completion
- 2011-11
Publications
- Results Marshall JR, Sakr W, Wood D, Berry D, Tangen C, Parker F, Thompson I, Lippman SM, Lieberman R, Alberts D, Jarrard D, Coltman C, Greenwald P, Minasian L, Crawford ED. Design and progress of a trial of selenium to prevent prostate cancer among men with high-grade prostatic intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev. 2006 Aug;15(8):1479-84. doi: 10.1158/1055-9965.EPI-05-0585.
- Results Sakr WA, Faulkner JR, Wood D: Low rate of confirming prostate cancer on repeat biopsies following diagnosis of high grade prostatic intraepithelial neoplasia: preliminary analysis of Southwest Oncology Group study s9917. [Abstract] Proceedings of the American Association for Cancer Research 45: A-1333, 305, 2004.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Selenomethionine | Other / unclassified | 200 ug | Oral |